Dr. Cush is joined by rheumatology colleagues to discuss impressions and impact of the 9/1/21 FDA Drug Safety Communication to physicians regarding new label changes. #RheumNow https://t.co/F37SCpJnsW https://t.co/uhdOjFo0yP